Global Translational Regenerative Medicine Market Prospects 2017-2027

LONDON, April 21, 2017 /PRNewswire/ --

Stem Cell Therapies, Tissue Engineered Products, Gene Therapies

The translational regenerative medicine market has been undergoing considerable changes over the last few years. There are a number of therapies that have been launched into the market over the last few years. Stem cell therapies are being developed constantly and these are targeted at various indications, from the more common cardiovascular conditions to rarer orphan indications.

The Global Translational Regenerative Medicine market is expected to grow significantly over the forecast period. The Global Translational Regenerative Medicine market was valued at $5.8bn in 2016. Visiongain forecasts this market to increase to $14.5bn in 2021. The market is estimated to grow at a CAGR of 19.9% in the first half of the forecast period and 17.7% from 2016 to 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you find 316-page report you will receive 107 tables and 66 figures - all unavailable elsewhere.

The 316-page report provides clear detailed insight into the Global Translational Regenerative Medicine market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
• Global Translational Regenerative Medicine market forecasts from 2017-2027

• Translational Regenerative Medicine regional market forecasts from 2017-2027, covering:
- United States
- Europe
- Asia-Pacific
- Rest of the World

• Global Translational Regenerative Medicine submarket forecasts from 2017-2027 covering:
- Stem Cell Therapies
- Tissue Engineered Products
- Gene Therapies

• Forecasts from 2017-2027 of the leading products in the Global Translational Regenerative Medicine market:
- Osteocel Plus
- Trinity ELITE
- TEMCELL /Prochymal
- Apligraf
- Dermagraft
- Epifix
- ReCell
- Neovasculgen
- Glybera (alipogene tiparvovec)
- IMLYGIC (talimogene laherparepvec)

• Assessment of the leading companies in the Global Translational Regenerative Medicine market:
- Alphatec Spine
- Anterogen
- Athersys
- Avita Medical
- AxoGen
- Medipost
- Mesoblast
- NuVasive
- Ocata Therapeutics
- Organogenesis
- Osiris Therapeutics
- Pharmicell
- Regenerys
- TiGenix
- UniQure
- Vericel Corporation

• SWOT and Porter's Five Force analysis of the translational regenerative medicine market

Visiongain's study is intended for anyone requiring commercial analyses for the Translational Regenerative Medicine Market and leading companies. You find data, trends and predictions.

Buy our report today Global Translational Regenerative Medicine Market Prospects 2017-2027: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100

Or click on https://www.visiongain.com/Report/1843/Global-Translational-Regenerative-Medicine-Market-Prospects-2017-2027

The companies mentioned are:

Advanced BioHealing
Advanced Tissue Sciences
Advantagene
AlloSource
AlphaTec Spine
Amedica
Amgen
Amorcyte
Amorepacific Group
AnGes MG
Angioblast Systems
Anika Therapeutics
Anterogen
Apceth
Arcarios B.V
Ark Therapeutics
Athersys Inc
Avita Medical
AxoGen
Baxter
Beike Biotechnology
Benda Pharmaceutical
BioD
Bioheart
BioMed Realty Trust, Inc
BioSante Pharmaceuticals
BioTime
BioTissue AG
BioVex Inc
Blackstone Medical
BrainStorm Cell Therapeutics
Caladrius Biosciences
California Stem Cell Inc
Capricor
Cardio3BioSciences
Celgene
Cell Targeting
CellCo Tec
Cellerant Therapeutics
Cephalon
Ceregene
CHA Biotech
Chiesi Farmaceutici
Cipla
Co.don AG
Cold Genesys
Cook Biotech Inc
Cytomedix
Cytori Therapeutics
Daiichi Sankyo
DePuy Mitek (Johnson & Johnson)
FibroCell Science
Gamida Cell Ltd
Genzyme Corporation (Sanofi)
Histogenics
Humacyte
Human Stem Cell Institute
Insulete Inc
Interxon Corporation
ISTO Technologies
Janssen Biotech Inc
Japan Tissue Engineering Co
JCR Pharmaceuticals
Johnson & Johnson
Kinetic Concept Inc
LecTec Corporation
Lincoln Park Capital
Lonza
MacroCure
Medipost
Medtronic
Mesoblast
Mitsubishi Tanabe
Myriad Genetics
Neostem
Neuralstem
Nippon Zoki Pharmaceuticals
NuVasive
Ocata Therapeutics
OncoCyte
Organovo
Orphan Biovitrum AB (Sobi)
Orthofix
Orteq Ltd.
Osiris Therapeutics
Oxford BioMedica
Parcell Laboratories
Pfizer
Pharmicell
Regenerys
Reliance Life Sciences
ReNeuron
RTI Surgical
Rusnano Corporation
Sangamo Biosciences
Sanofi
Shanghai Sunway Biotech
Shenzhen Sibiono GeneTech
Shire
Singapore General Hospital
Skye Orthobiologics
Smith & Nephewbv
Sobi Partners
Spark Therapeutics
StemCells Inc.
Stempeutics Research
Stratatech Corporation
TCA Cellular Therapy
Tengion Inc
Teva Pharmaceuticals
TiGenix
UniQure
U.S. Stem Cell Inc.
Vericel Corporation
Viacyte Inc
Vital Therapies
WKD Holding Oy
Xcellerex
Xenetic Biosciences
Zimmer

List of Organisations Mentioned in the Report
Arthritis Research UK
Associazione Infermieristica per lo Studio delle Lesioni Cutanee (AISLeC) [China]
Australian Regenerative Medicine Institute
Australian Sports Anti-Doping Authority (ASADA)
Biomedical Advanced Research and Development Authority (BARDA)
British Heart Foundation [UK]
California Institute of Regenerative Medicine (CIRM)
Cambridge Stem Cell Biology Institute [UK]
Case Western Reserve University
Catalan Institution for Research and Advanced Studies
Center for Biologics Evaluation and Research (CBER) [US]
CHA General Hospital [Korea]
Cryocenter Saint Petersburg
Drugs Controller General of India (DCGI)
European Group for Blood and Marrow Transplantation (EBMT)
European Medicines Agency
Food and Drugs Agency (FDA) [US]
Haute Autorité de santé [France]
Heriot-Watt University
Human Fertilisation and Embryology Authority (HFEA)
Institute of Biomedical Research and Innovation Hospital [Japan]
International Society for Stem Cell Research (ISSCR)
Karolinska Institute [Sweden]
Massachusetts General Hospital (MGH)
Mayo Clinic [US]
Medical Research Council [UK]
MiMedx
Ministry of Food and Drug Safety, MFDS) [Korea]
Ministry of Health, Labour and Welfare (MHLW) [Japan]
Ministry of Science and Technology [China]
Moorfields Eye Hospital
National Tissue Engineering Center (NTEC) [China]
New York Blood Center
Riken Center for Developmental Biology
RUSH University Medical Center [US]
Russian Ministry of Healthcare and Social Development
Scottish Centre for Regenerative Medicine
St. Jude's Children Research Hospital
State Food and Drug Administration (SFDA) [China]
SUNY Upstate Medical University
The Genetico Center [Russia]
The StemGen Organisation
Therapeutics Goods Administration (TGA) [Australia]
UH San Diego Sanford Stem Cell Clinical Center
UK Medicines and Healthcare Products Regulatory Agency (MHRA)
Universitat Autònoma de Barcelona [Spain]
University College London
University of Edinburgh MRC Centre for Regenerative Medicine [UK]
University of Massachusetts (UMass) Memorial Hospital
University of Modena Centre for Regenerative Medicine [Italy]
University of Wisconsin
US National Institute of Health
Wake Forest Institute
Wellcome Trust
World Health Organization

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain Ltd